CT ¼ chemotherapy; PS ¼ performance status; HDT ¼ high-dose therapy; CR ¼ complete remission; PR ¼ partial remission; SD ¼ stable disease; FFP ¼ freedom from progression (from second melphalan); OS ¼ overall survival (from second melphalan).
Ovarian cancer is the fourth leading cause of cancer-related death in women. There is no proven curative therapy for patients with ovarian cancer relapsing after platinumcontaining regimens. 1, 2 High-dose chemotherapy with autotransplantation does not seem strikingly superior to standard therapy for resistant/relapsed disease and is often associated with significant toxicity. 3, 4 However, the Norton-Simon model of tumor-growth kinetics predicts that multiple, rapidly cycled treatments yield better results compared with a single treatment. 5 Based on this hypothesis and the existence of an in vivo dose effect of alkylating agents in ovarian cancer, 6 we started a pilot study to evaluate the tolerability of double intermediate-dose melphalan supported by autologous stem cells in patients with refractory ovarian cancer and poor performance status. The interval between the two courses of melphalan was at least 45-60 days to avoid excessive toxicity in these heavily pre-treated patients.
In total, 10 patients with advanced ovarian cancer (FIGO stages III/IV) were enrolled from April 2000 to February 2003. All patients were pretreated: five had received two chemotherapy lines and five had undergone three lines. All patients had received platinum-and taxolcontaining regimens, and six patients had also received topotecan alone or in combination. The median time between platinum administration and disease progression was 3 months (range 1-5 months). At the time of the experimental therapy, median age was 52 (range 33-68) and the median time from diagnosis was 24 months (range 9-51). Nine patients had progressive disease (PD), and one was in partial remission (PR) after the last treatment. Seven patients had poor performance status (ECOGX2). Other patient characteristics are shown in Table 1 . In all but one patient, cyclophosphamide 4.5 g/m 2 plus G-CSF (5 mg/kg/ day, s.c.) was used to mobilize stem cells. One patient, failing mobilization with this, was mobilized with G-CSF alone (10 mg/kg/day, s.c.). Mobilization chemotherapy was tolerated well and the median number of CD34 þ cells per kg collected was 5.1 Â 10 6 (range 2.9-7.4). Patients received two cycles of intravenous melphalan at a dose of 100 mg/m 2 , each followed 24 h later by stem cells. The number of CD34 þ cells/kg reinfused following both high-dose cycles was similar (2.0 Â 10 6 , first cycle and 2.3 Â 10 6 , second cycle). All patients were discharged the day after stem cell reinfusion, and were assessed for toxicity on a daily basis. Tandem transplantation was well tolerated. Cycle 2 was delivered at a median of 50 days after cycle 1 (range 42-67). No toxic deaths occurred. Engraftment was rapid after both melphalan administrations: the median time to neutrophil recovery (ANCX0.5) was 11.5 and 12.5 days and platelet recovery (X20) was 12.5 and 13.5 days. Grade III-IV neutropenia and thrombocytopenia occurred in 80% of cases, with six patients requiring platelet transfusions. Red blood-cell transfusions were required in three cases. Nonhematological toxicity was limited to grade I-II mucositis and grade I diarrhea. Grade II-III fever complicated 20% of all cycles and one patient had Staphylococcus aureus bacteremia. Overall, only three of 20 cycles (15%) resulted in hospital admission for toxicity management. Tandem melphalan converted the patient with PR into CR. Of the nine patients with PD, five patients showed a partial response (PR), and four had a disease stabilization. Interestingly enough, all patients had a marked improvement in performance status after therapy. With a median follow-up of 12 months (range 4-21), five patients are alive with disease, and one is in complete remission. The median freedom from progression (FFP) was 5 months and median survival from the end of therapy was 12 months. At present, three out of five patients remain with stable disease at 21, 4, and 3 months after tandem transplantation without any other additional chemotherapy. In ovarian cancer, high-dose carboplatin, cyclophosphamide, melphalan, etoposide/teniposide, busulphan, and topotecan have been used prior to autografting. [7] [8] [9] [10] Treatment-related mortality reported in the literature varies from 0 to 13%, suggesting an important center effect and patient selection. Furthermore, after high-dose chemotherapy, patients remained hospitalized for intensive supportive care with antibiotics, transfusions, and analgesia. No randomized studies have been conducted to establish if single-agent high-dose chemotherapy produces fewer objective responses in solid tumors. Our approach of two cycles of intermediate-dose chemotherapy seems to have been tolerated better than highdose therapy. 11 Several drugs, singly or in combination, have been used to treat patients with platinum relapse/refractory disease with response rates of 10-30%, median survival of about 10 months, and significant toxicity. [12] [13] [14] [15] Comparisons between published data and our findings are obviously difficult, but two rounds of intermediate-dose melphalan did not seem to be more toxic and yielded similar clinical results. However, prospective studies are required to explore these findings further. 
